Alessi E, Cusini M, Zerboni R, Calvicchini S, Uberti-Foppa C, Galli M, Moroni M. Unusual varicella zoster virus infection in patients with the acquired immunodeficiency syndrome. Arch Dermatol. 1988; 124: 1011-1013.

Alter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. Infect Control. 1986 ;7: 448-51.

American Academy of Pediatrics committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. Pediatrics 1993; 91: 674-676.

American academy of pediatrics committee on Infectious Diseases. Recommendation for the use of live attenuated varicella vaccine. pediatrics1995; 95: 791-796.

Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden DH. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol. 1995 ;37: 784-90.

Anderson DR, Schwartz J, Hunter NJ, Cottrill C, Bisaccia E, Klainer AS. Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult. Report of a case, autopsy, and review of the literature. Arch Intern Med. 1994 26;154: 2101-6.

Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis. 1983; 148: 200-5.

Arvin AM, Koropchak CM, B.R.G. Williams, F.C.Grumet, and S.K.H. Foung. The early immune response in healthy and immuno compromised subjects with primary varicella zoster virus infection, J. Infect Dis. 1986; 154: 422-429.

Arvin AM, Sharp M, Smith S, Koropchak CM, Diaz PS, Kinchington P, Ruyechan W, Hay J. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991;146: 257-64.

Arvin AM. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992;166 Suppl 1:S35-41.

Arvin, A.M. Varicella-zoster virus, 1995; P. 2547-2586. In B. Fields (ed.), virology, 3rd ed. Raven press New York.

Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996; 9: 361-81.

Arvin AM. Varicella-zoster virus. In: Fields BN. Knipe DM. Howley PM. Et al, eds. Fields virology 3rd ed. New York: lippincott Raven: 1996: 2547.

Asano Y, Itakura N, Kajita Y, Suga S, Yoshikawa T, Yazaki T, Ozaki T, Yamanishi K, Takahashi M. Severity of viremia and clinical findings in children with varicella. J Infect Dis. 1990;161:1095-8.

Asano Y, Suga S, Yoshikawa T, Kobayashi I, Yazaki T, Shibata M, Tsuzuki K, Ito S. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994; 94: 524-6.

Balducci J, Rodis JF, Rosengren S, Vintzileos AM, Spivey G, Vosseller C. Pregnancy outcome following first-trimester varicella infection. Obstet Gynecol. 1992; 79: 5-6.

Balfour HH Jr. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med. 1988; 29; 85: 68-73.

Balfour HH Jr, Benson C, Braun R, Cassens B, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr. 1994; 7: 254-60.

Balfour HH Jr, Rotbart HA, Feldman S, et al. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group. J Pediatr. 1992; 120: 627-33.

Barnes DW, Whitley RJ. CNS diseases associated with varicella zoster virus and herpes simplex virus infection. Pathogenesis and current therapy. Neurol Clin. 1986 ;4: 265-83

Bartoloni A, Bartalesi F, Roselli M, Mantella A, Dini F, Carballo ES, Barron VP, Paradisi F. Seroprevalence of varicella zoster and rubella antibodies among rural populations of the Chaco region, south-eastern Bolivia. Trop Med Int Health. 2002; 7: 512-7.

Barzaga NG, Roxas JR, Florese RH: Varicella zoster virus prevalence in Metro Manila, Philippines. J Am Med Assoc (SEAsia) 1994; 274: S633-S635.

Bennett G.J. hypothesis on the pathogenesis of herpes zoster associated pain. Ann. Neurol. 1994; 35: S38-S41.

Berger R, Luescher D, Just M. Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis. 1984;149: 647.

Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocomptent adults. Antimicrob Agents Chemother. 1995; 39: 1546-53.

Bhattarakosol P, Chantarabul S, Pittayathikhun K, Mung-mee V, Punnarugsa V. Prevalence of anti-varicella zoster IgG antibody in undergraduate students. Asian Pac J Allergy Immunol. 1996; 14: 129-31.

Bogger-Goren S, Baba K, Hurley P, Yabuuchi H, Takahashi M, Ogra PL. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis. 1982; 146: 260-4.

Bogger-Goren S, Bernstein JM, Gershon AA, Ogra PL. Mucosal cell-mediated immunity to varicella zoster virus: role in protection against disease. J Pediatr. 1984;105:195-9.

Boivin G, Edelman CK, Pedneault L, Talarico CL. Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis. 1994; 170: 68-75.

Brinker JP, Doern GV. Comparison of MRC-5 and A-549 cells in conventional culture tubes and shell vial assays for the detection of varicella-zoster virus. Diagn Microbiol Infect Dis. 1993; 17: 75-7.

Brisson M, Gray NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002 7; 20: 2500-7.

Brunell PA, Novelli VM, Keller PM, Ellis RW. Antibodies to the three major glycoproteins of varicella-zoster virus: search for the relevant host immune response. J Infect Dis. 1987;156: 430-5.

Brunell, P.A. Transmission of chickenpox in a school setting prior to the observed exanthem. Am. J. dis. Child. 1989; 143: 1451-1452.

Brunell PA. Varicella in pregnancy, the fetus, and the newborn: problems in management. J Infect Dis. 1992; 166 Suppl 1: S42-7.

Can. Commun Dis. Rep. 2004 Feb 1; 30: 1-26.

Canadian Immunization guide, 6th ed. Immunization in immunocompromised hosts. Ottawa: Health Canada, 2002: 20 – 30 catalogue No. H 49 – 8 / 2002 E.

Canadian Immunization guide, 6th ed. *Varicella vaccine, in: Health Canada Ottawa, 2002:223-32. Catalogue no. H49-8/2002E.*

Canadian task force on preventive health care. New grades for recommendations from the Canadian task force on preventive Health Care. Can Med Assoc J 2003; 169: 207-8.

Centers for Disease Control. Varicella-zoster immune globulin for the prevention of chickenpox: recommendations of the immunization practices advisory committee. Ann. Intern. Med. 1984; 100: 859-865.

Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the advisory Committee on Immunization practices (ACIP). MMWR 1996; 45: 1-36.

Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, Tudehope DI, Tilse M. Varicella-zoster virus infection in Australia. Aust N Z J Public Health. 1998;22: 413-8.

Clements DA, Moreira SP, Coplan PM, et al. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J. 1999; 18: 1047-50.

Cohen, J.I. and S.E. Straus. 1995: Varicella-zoster virus and its replication P. 2525-2546. in B. Fields (ed.), virology, 3rd ed. Raven press, New York.

Cohen PR, Grossman ME. Clinical features of human immunodeficiency virus-associated disseminated herpes zoster virus infection--a review of the literature. Clin Exp Dermatol. 1989; 14: 273-6.

Cowan MR, Primm PA, Scott SM, Abramo TJ, Wiebe RA. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med. 1994;23: 818-22.

Croen KD, Ostrove JM, Dragovic LJ, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A. 1988; 85: 9773-7.

Cuthbertson G, Grose C. Biotinylated and radioactive DNA probes for detection of varicella-zoster virus genome in infected human cells. Mol Cell Probes. 1988; 2: 197-207.

David Greenwood, Richard C.B.Slack and John F. Peutherer: Medical Mierobiology: 1998. 410.

Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol. 1986;67: 1759-816.

Demmler GJ, Steinberg SP, Blum G, et al. Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella-zoster virus. J Infect Dis. 1988; 157: 211-2.

Dennehy PH, Reisinger KS, Blatter MM, et al. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics. 1991; 88: 604-7.

Devlin ME, Gilden DH, Mahalingam R, Dueland AN, Cohrs R. Peripheral blood mononuclear cells of the elderly contain varicella-zoster virus DNA. J Infect Dis. 1992; 165: 619-22.

Dumas AM, Geelen JL MC, Maris W, et al,: Infectivity and molecular weight of varicellar zoster virus DNA. J Gen viol 1980; 47: 233-235.

Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991 28; 325: 1539-44.

Dworkin RH. Racial differences in herpes zoster and age at onset of varicella. J Infect Dis. 1996 ;174:239-40.

Dworsky, M. R. J. Whitley, and C. Alford. Herpes zoster in early, infancy. Am. J. Dis. Child. 1980; 134: 618-620.

Earnshaw DL, Bacon TH, Darlison SJ, Edmonds K, et al. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother. 1992; 36: 2747-57.

Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994; 18;343(8912):1548-51.

Englund JA, Arvin AM, Balfour HH Jr. Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. J Clin Microbiol. 1990; 28: 2327-33.

Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr. 1989 ; 114: 37-44.

Ey JL, Fulginiti VA. Varicella hepatitis without neurologic symptoms or findings. Pediatrics. 1981;67: 258-263.

Fairly CK, Miller E. Varicella zoster virus epidemiology- A changing Scene. J Infect Dis. 1996; 174 (suppl): S 314- S319.

Feldman SR, Ford MJ, Briggaman RA. Herpes zoster and facial palsy. Cutis. 1988;42: 523-4.

Feldman SR, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987; 80: 465-72.

Fleisher G, Henry W, McSorley M, Arbeter A, Plotkin S. Life-threatening complications of varicella. Am J Dis Child. 1981;135: 896-9.

Flisser A, Quintanilla GF, Mngos C, Conyer TR: The last 10 years: changing epidemiology of varicella virus. Virus life 1997; 16: 12-15.

Forghani, B., L. Ni, and C. Grose: Neutralization epitope of the varicella-zoster virus gH: gL glycoprotein complex. Virology 1994; 199: 458-462.

Forghani B, Van Loon F, MC Quillan G, et al: Determination of antibody status to VZV in the US population [Abstract B_{10}] In: second International conference on the varicella-zoster virus, Paris, July 7 to 8, 1994. New York: varicella zoster virus foundation 1994.

Forghani B, Yu GJ, Hurst JW. Comparison of biotinylated DNA and RNA probes for rapid detection of varicella-zoster virus genome by in situ hybridization. J Clin Microbiol. 1991; 29: 583-91.

Furuta Y, Takasu T, Fukuda S, Sato-Matsumura KC, et al,. Detection of varicella-zoster virus DNA in human geniculate ganglia by polymerase chain reaction. J Infect Dis. 1992; 166: 1157-9.

Gabutti G, Penna C, Rossi M, et al: The sero epidemiology of varicella in Italy. Epidemiol Infect 2001; 126: 433-440

Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, Montero J, Seward J. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002; 347: 1909-15.

Garland J. varicella following exposure to herpes zoster. N Engl J Med. 1943: 228-336.

Garnett GP, Cox MJ, Bundy DA, Didier JM, St Catharine J. The age of infection with varicella-zoster virus in St Lucia, West Indies. Epidemiol Infect. 1993;110:361-72.

Gershon AA, Steinberg SP. Antibody responses to varicella-zoster virus and the role of antibody in host defense. Am J Med Sci. 1981; 282: 12-7.

Gershon, AA, Steinberg SP, L. Gelb, G. Galasso et al.: live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984; 252: 355-362.

Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis. 1984;149:137-42.

Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis. 1988;158: 132-7.

Gershon AA, Steinberg SP. Persistence of immunity to varicella in children with leukemia immunized with live attenuated varicella vaccine. N Engl J Med. 1989 6; 320: 892-7.

Gershon AA, Steinberg SP. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J Infect Dis. 1990; 161: 661-6.

Gershon AA. Human immune responses to live attenuated varicella vaccine. Rev Infect Dis. 1991; 13 Suppl 11: S957-9.

Gershon AA., Steinberg SP., and NJ. Schmidt. Varicella-zoster virus, 1991; P. 838-852. In A. Balows, W.J. Hausler, K.L. Herrman. H.D. Isenberg, and H.J. Shadomy (ed.), Manual of clinical microbiology. American society for Microbiology, Washington, D, C.

Gershon AA. Varicella vaccine: its past, present and future. Pediatr. Infect Dis J 1995; 14: 742-744.

Gershon AA. Varicella vaccine: rare serious problems--but the benefits still outweigh the risks. J Infect Dis. 2003;188: 945-7.

Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect. 2003;131:1085-9.

Gilden D.H., Beinlich B.R., Rubinstein E.M., Stommel E., Swenson R., Rubinstein D. and Mahalingam R. Varicella zoster virus myelitis: an expanding spectrum. Neurology 1994; 44: 1818-23.

Gilden DH, Dueland AN, Devlin ME, Mahalingam R, Cohrs R. Varicella-zoster virus reactivation without rash. J Infect Dis. 1992; 166 Suppl 1:S30-4.

Gilden DH, Wright RR, Schneck SA, Gwaltney JM Jr, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol. 1994; 35:530-3.

Giller RH, Winistorfer S, Grose C. Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis. 1989;160: 919-28.

Gleaves CA, Schwarz KA, Campbell MB. Determination of varicella-zoster virus (VZV) immune status with the VIDAS VZV immunoglobulin G automated immunoassay and the VZVScan latex agglutination assay. Clin Diagn Lab Immunol. 1996; 3: 365-7.

Gnann JW Jr. New antivirals with activity against varicella-zoster virus. Ann Neurol. 1994;35 Suppl:S69-72.

Gogos CA, Bassaris HP, Vagenakis AG. Varicella pneumonia in adults. A review of pulmonary manifestations, risk factors and treatment. Respiration. 1992; 59: 339-43.

Gray F, Belec L, Lescs MC, Chretien F, Ciardi A, Hassine D, Flament-Saillour M, de Truchis P, Clair B, Scaravilli F. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain. 1994;117: 987-99.

Gray GC, Palinkas LA, Kelley PW. Increasing incidence of varicella hospitalizations in United States Army and Navy personnel: are today's teenagers more susceptible? Should recruits be vaccinated? Pediatrics. 1990; 86: 867-73.

Grose C. Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics. 1981;68: 735-7.

Grose C. Glycoproteins of varicella-zoster virus and their herpes simplex virus homologs. Rev Infect Dis. 1991;13 Suppl 11:S960-3.

Grose C, Ng TI. Intracellular synthesis of varicella-zoster virus. J Infect Dis. 1992; 166 Suppl 1:S7-12.

Guess, H.A., D.D. Broughton, L.J. Melton II, and L.T. Kurland.. Population – based studies of varicella complications. Pediatrics 1987; 78: 723-727.

Gustafson, T.L., G.B. Lavely, E.R. Brawner, Jr., R.H. Hutcheson, Jr. P.F. wright, and w. shcaffner.. An outbreak of airborne nosocomial varicella. Pediatrics 1982; 70: 550-556.

Haake DA, Zakowski PC, Haake DL, Bryson YJ. Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis. 1990; 12: 788-98.

Hacham M, Leventon-Kriss S, Sarov I. Enzyme-linked immunosorbent assay for detection of virus-specific IgM antibodies to varicella-zoster virus. Intervirology. 1980;13: 214-22.

Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Second varicella infections: are they more common than previously thought? Pediatrics. 2002 109:1068-73.

Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol. 1994 15; 140: 81-104.

Hammerschlag MR, Gershon AA, Steinberg SP, Clarke L, Gelb LD. Herpes zoster in an adult recipient of live attenuated varicella vaccine. J Infect Dis. 1989;160: 535-7.

Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13: 277-83.

Hardy I, Gershon AA, Steinberg SP and LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991 28; 325: 1545-50.

Hastie IR. Varicella-zoster virus affecting immigrant nurses. Lancet. 1980; 19;2: 154-5.

Hayward, A.R., and M. Herberger.. Lymphocyte responses to varicella-zoster virus in the elderly. J. Clin. Immunol. 1987; 7: 174-178.

Hayward AR. T-cell responses to predicted amphipathic peptides of varicella-zoster virus glycoproteins II and IV. J Virol. 1990; 64: 651-5.

Hayward AR, Levin M, Wolf W, Angelova G, Gilden D. Varicella-zoster virus-specific immunity after herpes zoster. J Infect Dis. 1991;163: 873-5.

Hellinger WC, Bolling JP, Smith TF, Campbell RJ. Varicella-zoster virus retinitis in a patient with AIDS-related complex: case report and brief review of the acute retinal necrosis syndrome. Clin Infect Dis. 1993;16: 208-12.

Hilt DC, Buchholz D, Krumholz A, Weiss H, Wolinsky JS. Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol. 1983;14: 543-53.

Holmes SJ, Reef S, Handler SC, et al: Prevention of varicella: Recommendations of the Advisory committee on Immunization practices. MMWR Morb Mortal Wkly Rep 1996; 12: 1-36.

Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.

Huang YC, Lin TY, Chiu CH. Acyclovir prophylaxis of varicella after household exposure. Pediatr Infect Dis J. 1995; 14: 152-4.

Huff JC, Drucker JL, Clemmer A, Laskin OL, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol. 1993; Suppl 1: 93-6.

Hughes P, LaRussa P, Pearce JM, Lepow M, et al,. Transmission of varicella-zoster virus from a vaccinee with leukemia, demonstrated by polymerase chain reaction. J Pediatr. 1994; 124: 932-5.

Hurwitz ES, Goodman RA. A cluster of cases of Reye syndrome associated with chickenpox. Pediatrics. 1982;70: 901-6.

Ihara T, Kamiya H, Torigoe S, Sakura M, Takahashi M. Viremic phase in a leukemic child after live varicella vaccination. Pediatrics. 1992; 89: 147-9.

Ilobi CP, Martin BA. A simple and sensitive assay for varicella-zoster virus. J Virol Methods. 1989; 2: 137-48.

Jackson MA, Burry VF, Olson LC. Complications of varicella requiring hospitalization in previously healthy children. Pediatr Infect Dis J. 1992; 11: 441-5.

Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine (Baltimore). 1983;62: 81-97.

Jerant AF, DeGaetano JS, Epperly TD, Hannapel AC, Miller DR, Lioyd AJ. Varicella susceptibility and vaccination strategies in young adults. J Am Board Fam Pract. 1998;11:296-306.

Jezek Z, Hardjotanojo W, Rangaraj AG. Facial scarring after varicella. A comparison with variola major and variola minor. Am J Epidemiol. 1981; 114:793-803.

Jorm LR, Capon AG. Communicable disease outbreaks in long day care centres in western Sydney: occurrence and risk factors. J Paediatr Child Health. 1994;30:151-4.

Kangro HO, Ward A, Argent S, Heath RB, et al. Detection of specific IgM in varicella and herpes zoster by antibody-capture radioimmunoassay. Epidemiol Infect. 1988; 101: 187-95.

Kanra G, Tezcan S, Badur S, Turkish National study team. Varicella seroprevalence in a random sample of the Turkish population. Vaccine 2002; 20: 1425-1428.

Kappagoda C, Shaw P, Burgess M, Botham S, Cramer L. Varicella vaccine in non-immune household contacts of children with cancer or leukaemia. J Paediatr Child Health. 1999;35: 341-5.

Karbassi M, Raizman MB, Schuman JS. Herpes zoster ophthalmicus. Surv Ophthalmol. 1992;36: 395-410.

Kelley PW, Petruccelli BP, Stehr-Green P, Erickson RL, Mason CJ. The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. JAMA. 1991;266:2724-9.

Khairnullah NS, Wang CK, Koh CG. Prevalence of varicella zoster virus antibodies in the University Hospital, Kuala Lumpur, Malaysia. Proceedings of 5th Western Pacific Congress on chemotherapy and infectious Diseases, 1996; P 184.

KinChington, P.R., J.K. Houghland, A.M. Arvin, W.T. Ruyechan, and J. Hay.. Varicella-zoster virus IE62 protein is a major virion component. J. virol. 1992; 66: 359-366.

Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med. 1990; 18: 171- 4.

Koropchak CM, Graham G, Palmer J, Winsberg M, Ting SF, Wallace M, Prober CG, Arvin AM. Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis. 1991;163: 1016-22.

Koropchak CM, Solem SM, Diaz PS, Arvin AM. Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol. 1989;63:2392-5.

Krah DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am. 1996;10: 507-27.

Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr. 1995;127: 518-25.

Landry ML, Cohen SD, Mayo DR, Fong CK, et al. Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus. J Clin Microbiol. 1987; 25: 832-5.

Landry ML, Ferguson D. Comparison of latex agglutination test with enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus. J Clin Microbiol. 1993; 30: 3031-3.

Lau YL, Vessey SJ, Chan IS, et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine. 2002 26; 20: 2942-9.

Leclair JM, Zaia JA, Levin MJ, Congdon RG, Goldmann DA. Airborne transmission of chickenpox in a hospital. N Engl J Med. 1980; 21;302: 450-3.

Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health. 1998; 3: 886-90

Lerman SJ: why is chickenpox called dickenpox? Clin. Pediatr 1981; 20: 111-112.

Leslie collier, Albert Balows, Max Sussman. Microbiology and Microbiol infections. 1, 331-336. 1998.

Lever, WF and G. Schaumburg-lever. Histopathology of the skin. 1990; P404-406. J.B. Lippincott co., Philadelphia

Levin MJ, Gershon AA, Weinberg A, et al,. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001; 139: 305-10.

Levin MJ, Murray M, Zerbe GO, White CJ, Hayward AR. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis. 1994;170: 522-6.

Levy O, Orange JS, Hibberd P, et al,. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 2003; 188: 948-53.

Li S, Chan IS, Matthews H, et al. Inverse relationship between six weeks postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002; 21: 337-42.

Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994 2; 271: 375-81.

Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics. 1995; 95: 632-8.

Liu GT, Urion DK. Pre-eruptive varicella encephalitis and cerebellar ataxia. Pediatr Neurol. 1992; 8: 69-70.

Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985; 152: 1172-81.

Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J, Bock HL, Kanwal S, Shah RC, Shah N. Age related seroprevalence of antibodies to varicella in India. Indian Pediatr. 2000; 37: 714-9.

Longfield JN, Winn RE, Gibson RL, Juchau SV, Hoffman PV. Varicella outbreaks in Army recruits from Puerto Rico. Varicella susceptibility in a population from the tropics. Arch Intern Med. 1990; 150: 970-3.

Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992; 90: 216-20.

Machida H, Nishitani M. Drug susceptibilities of isolates of varicella-zoster virus in a clinical study of oral brovavir. Microbiol Immunol. 1990; 34: 407-11.

Mahalingam R, Wellish M, Lederer D, Forghani B, Cohrs R, Gilden D. Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase chain reaction. J Virol. 1993; 67: 2381-4.

Mandal BK, Mukherjee PP, Murphy C, Mukherjee R, Naik T. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis. 1998;178 Suppl 1:S52-4.

Martin G. Myers, Lawrence R. Stanberry, and Jane F. Seward. Varicella zoster virus in: Behrman RE, Kliegman RM, Jenson HB (eds.). Nelson text book of pediatrics, 16th ed. Philadelphia, W,B. saunders co., 2004; P. 1057 – 1062.

McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC Jr. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics. 1989; 83: 256-61.

Medical Letter on Drugs and Therapeutics.. Famciclovir for herpes zoster. Med. Lett. Drugs Ther. 1994; 36: 97-98.

Migasena S, Simasthien S, Desa Korn V, Phonrat B, Suntharasamai P, Pitis Uttitham P, et al: Seroprevalence of varicella zoster virus anti-bodies in Thailand. Int. J Infect Dis. Children 1997; 2: 26-30.

Miller AE. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30: 582-7.

Miller E, Vardien J, Farrington P. Shift in age in chickenpox. Lancet. 1993;341:308-9.

Moffat JF, Stein MD, Kaneshima H, Arvin AM. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol. 1995; 69: 5236-42.

Munech R, Nassim C, Nikku S: Sero – epidemiology of varicella. J. infect Dis 1986; 153: 153-155.

Murray DL, Lynch MA: Determination of immune status to measles, rubella and varicella zoster virus among medical students. Am J Public Health 1986; 78: 836-838.

Nader S, Bergen R, Sharp M, Arvin AM. Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995; 171: 13-7.

National Advisory Committee on Immunization: Update to the statement on varicella vaccine. CCDR 2002: 28(ACS-3): 1-7.

Naus M, King A, Bowmer I, De serres G, Dobson S, et al., An Advisory committee statement (ACS). National Adivsory committee on Immunization (NACI). Update on Varicella: 2004; 30: 1-26.

Ndume PM, Cradock-Watson J, Levinski RJ. Natural and artificial immunity to varicella zoster virus. J Med Virol. 1988; 25: 171-8.

O'Grady KA, Merianos A, Patel M, Gilbert L. High seroprevalence of antibodies to varicella zoster virus in adult women in a tropical climate. Trop Med Int Health. 2000; 5: 732-6.

Ooi PL, Goh KT, Doraisingham S, Ling AE. Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health. 1992; 23: 22-5.

Ozaki T, Ichikawa T, Matsui Y, Nagai T, Asano Y, Yamanishi K, Takahashi M. Viremic phase in nonimmunocompromised children with varicella. J Pediatr. 1984;104: 85-7.

Ozaki T, Kajita Y, Asano Y, Aono T, Yamanishi K. Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol. 1994; 44: 263-5.

Paryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella., N Engl J Med. 1986 12; 314: 1542-6.

Pastuszak AL, Levy M, Schick B, Zuber C, Feldkamp M, Gladstone J, Bar-Levy F, Jackson E, Donnenfeld A, Meschino W. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med. 1994 31; 330: 901-5.

Peck RW, Wootton R, Lee DR, Jackson SH, Posner J. The bioavailability and disposition of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)uracil (882C87), a potent, new anti-varicella zoster virus agent. Br J Clin Pharmacol. 1995; 39: 143-9.

Perren TJ, Powles RL, Easton D, Stolle K, Selby PJ. Prevention of herpes zoster in patients by long-term oral acyclovir after allogeneic bone marrow transplantation. Am J Med. 1988; 85: 99-101.

Peters AC, Versteeg J, Lindeman J, Bots GT. Varicella and acute cerebellar ataxia. Arch Neurol. 1978; 35: 769-784.

Plotkin SA, Starr SE, Connor K, Morton D. Zoster in normal children after varicella vaccine. J Infect Dis. 1989; 159: 1000-1

Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol. 1986; 20: 651-64.

Preblud S.R. Age specific risks of varicella complications. Pediatrics. 1981; 68: 14-18.

Preblud SR, Oreastein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis. 1984; 3:505-9.

Preblud SR, Bregman DJ, Vernon LL. Deaths from varicella in infants. Pediatr Infect Dis. 1985; 4: 503-7.

Preblud SR. Varicella: complications and costs. Pediatrics. 1986; 78: 728-35.

Prober CG, Gershon AA, Grose C, McCracken GH Jr, Nelson JD. Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J. 1990; 9: 865-9.

Prober CG, Kirk LE, Keeney RE. Acyclovir therapy of chickenpox in immunosuppressed children--a collaborative study. J Pediatr. 1982; 101: 622-5.

Product Monograph. Varilrix. Glaxo Smith Kline, September 12, 2002.

Product Monograph. Varivax III. Merck frost Canada Co. March 14, 2003.

Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine. 1991; 9: 111-6.

Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol. 1993;Suppl 1:139-45.

Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982; 61: 310-6.

Rawlinson WD, Dwyer DE, Gibbons VL, Cunningham AL. Rapid diagnosis of varicella-zoster virus infection with a monoclonal antibody based direct immunofluorescence technique. J Virol Methods. 1989; 23: 13-8.

Ronan K, Wallace MR. The utility of serologic testing for varicella in an adolescent population. Vaccine.2001 14;19:4700-2.

Room A: Room's Dictionary of Distinguishables. Boston, Routledge and Kegan Paul, 1981, P27.

Saddier P, Floret D, Guess HA, Durr F, Peyrieux JC, Weber DJ, Plotkin SA. Cost of varicella in France: a study in day care centers. J Infect Dis. 1998;178 Suppl 1:S58-63.

Sadzot-Delvaux C, Merville-Louis MP, Delree P, Marc P, Piette J, Moonen G, Rentier B. An in vivo model of varicella-zoster virus latent infection of dorsal root ganglia. J Neurosci Res. 1990;26: 83-89.

Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, et al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. Ann Intern Med. 1991; 115: 19-21.

Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner JL: Seroepidemiology of varicella-zoster virus infections in Catalonia (spain): rationale for universal vaccination programmes. Vaccine 2001; 19: 183-8.

Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994; 38: 2454-7.

Samir K., SAHA, Garyl. Darmstadt, et al, Sero epidemiology of VZV in Bangladesh, Annals of Tropical Pediatrics 2002, 22; 341-345.

Sawyer MH, Chamberlin CJ, Wu YN, Aintablian N, Wallace MR. Detection of varicella-zoster virus DNA in air samples from hospital rooms. J Infect Dis. 1994; 169: 91-4.

Sawyer MH, Wu YN, Chamberlin CJ, Burgos C, Brodine SK, Bowler WA, LaRocco A, Oldfield EC 3rd, Wallace MR. Detection of varicella-zoster virus DNA in the oropharynx and blood of patients with varicella. J Infect Dis. 1992;166: 885-8.

Scheifele DW, Halperin SA, Diaz-mitoma F. Three – year follow up of protection rates in children given vaiecella vaccine. Can J Infect Dis. 2002; 13: 382-86.

Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995;171: 701-4.

Schmidbauer M, Budka H, Pilz P, Kurata T, Hondo R. Presence, distribution and spread of productive varicella zoster virus infection in nervous tissues. Brain. 1992; 115: 383-98.

Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R. Herpes zoster infection after autologous bone marrow transplantation. Blood. 1989; 74: 1424-7.

Sharp M, Terada K, Wilson A, Nader S,. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis. 1992; 165: 852-8.

Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19: 916-23.

Shinefield HR, Black SB, Staehle BO, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002; 21: 555-61.

Spector T, Harrington JA, Morrison RW Jr, Lambe CU, et al. 2-Acetylpyridine 5-[(dimethylamino) thiocarbonyl] thiocarbonohydrazone (A1110U), a potent inactivator of ribonucleotide reductases of herpes simplex and varicella-zoster viruses and a potentiator of acyclovir. Proc Natl Acad Sci U S A. 1989; 86: 1051-5.

Srugo I, Israele V, Wittek AE, Courville T, Vimal VM, Brunell PA. Clinical manifestations of varicella-zoster virus infections in human immunodeficiency virus-infected children. Am J Dis Child. 1993;147: 742-5.

Starr SE. Varicella in children receiving steroids for asthma: risks and management. Pediatr. Infect. Dis. J. 1992; 11: 419-420.

Steinberg SP, Gershon AA. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol. 1991; 29: 1527-9.

Stevens DA, Merigan TC. Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Arch Intern Med. 1980; 140: 52-4.

Straus SE. Clinical and biological differences between recurrent herpes simplex virus and varicella-zoster virus infections. JAMA. 1989; 262: 3455-8.

Straus SE, Reinhold W, Smith HA, Ruyechan WT, Henderson DK, et al. Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N Engl J Med. 1984; 22: 1362-4.

Struewing JP, Hyams KC, Tuellor JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. Am J Public Health. 1993;83:1717-20.

Takahashi M. Current status and prospects of live varicella vaccine. Vaccine. 1992;10: 1007-14. Review.

Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360: 678-82.

Ulrich Heininger, Charlotte Braun – Fahrlander et al: Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity. Pediatr Infect Dis J. 2001; 20: 775-8.

Vafai A, Wellish M, Gilden DH. Expression of varicella-zoster virus in blood mononuclear cells of patients with postherpetic neuralgia. Proc Natl Acad Sci U S A. 1988; 85: 2767-70.

Venkitaraman AR, John TJ. The epidemiology of varicella in staff and students of a hospital in the tropics. Int J Epidemiol. 1984;13:502-5.

Venkitaraman AR, Seigneurin JM, Baccard M, Lenoir GM, John TJ. Measurement of antibodies to varicella-zoster virus in a tropical population by enzyme-linked immunosorbent assay. J Clin Microbiol. 1984; 20:582-3.

Ventura A. Varicella vaccination guidelines for adolescents and adults. Am Fam Physician. 1997; 55: 1220-4.

Von Bokay J. Uberden atiologischen zusammenhang der varizellen mit gewissen fallen von herpes zoster. Wein Klin Wochenschr 1909; 22: 1323-1326.

Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC 3rd.Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med. 1992; 17: 358-63.

Wallace MR, Chamberlin CJ, Sawyer MH, Arvin AM, Harkins J, LaRocco A, Colopy MW, Bowler WA, Oldfield EC 3rd. Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. J Infect Dis. 1996;174: 249-55.

Watson B, Boardman C, Laufer D, Piercy S, et al,. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis. 1995; 20: 316-319.

Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis. 1994; 169: 197-9.

Watson B, Seward J, Yang A, et al. Postexposure effectiveness of varicella vaccine. Pediatrics. 2000; 105: 85-8.

Watson CPN and Deck JH. The neuropathology of herpes zoster with particular reference to postherpetic neuralgia and its pathogenesis, 1993; P. 139-157. In CPN Watson (ed.), Herpes zoster and postherpetic neuralgia. Pain research and clinical management, vol. B Biomedical press, Amsterdam.

Weber DJ, Rutala WA, Hamilton H. Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol. 1996; 17: 694-705.

Weller TH, Stoddard MB. Intranuclear inclusion bodies in cultures of human tissue inoculated with varicella vesicle fluid. J Immunol. 1952 ;68:311.

Weller TH, Witton HM. The etiologic agents of varicella and herpes zoster; serologic studies with the viruses as propagated in vitro. J Exp Med. 1958; 228-336.

Weller TH. Varicella and herpes zoster: a perspective and overview. J Infect Dis. 1992;166 Suppl 1:S1-6. Review.

Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am. 1996;10:571-81.

Whitley, R.J. varicella. Zoster virus infections, 1990; P. 235-265. in G.J. Galasso, R.J. whitley, and T.C. Merigan (ed.), Antiviral agents and viral diseases of man. Raven press, New York.

Whitley RJ. Therapeutic approaches to varicella-zoster virus infections. J Infect Dis. 1992;166 Suppl 1:S51-7.

Whitley RJ Varicella zoster virus in: Mandell, Douglas and Benneit's principles and practice of infectious diseases (eds G1 Mandell, JE Bennet and R Dolin), 5th edn. Churchill Livingstone, New York PP. 2000; 1580- 1586.

Wilson A, Sharp M, Koropchak CM, Ting SF, Arvin AM. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992; 165: 119-26.

Wood MJ, Ogan PH, McKendrick MW, Care CD, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med. 1988; 85:79-83.

Yu AL, Costa JM, Amaku M, Pannuti CS, Souza VA, Zanetta DM, Burattini MN, Massad E, Azevedo RS. Three year seroepidemiological study of varicella-zoster virus in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2000; 42: 125-8.

Zaia JA, Levin MJ, Preblud SR, et al. Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis. 1983; 147: 737-43.

Zhang Y, Cosyns M, Levin MJ, Hayward AR. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol. 1994; 98: 128-33.

Zhu, Z., M.D. Gershon, R. Ambhron, C. Gabel, and A.A. Gershon. Infection of cell by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin. Proc. Natl. Acad. Sci. USA 1995; 92: 3546-3550.

Serial No.	
Personal history:	**Name:** **Age in years:** **Sex**: Male ☐ Female ☐ **Job**: worker ☐ Student ☐ governmental school ☐ private school ☐ **Residence**: urban ☐ rural ☐ **Number of siblings**: ☐
Parental education:	**Father** Illiterate ☐ read and write ☐ Moderate ☐ graduate ☐ **Mother** Illiterate ☐ read and write ☐ Moderate ☐ graduate ☐
Parental occupation	**Father:** **Mother:** housewife ☐ working mother ☐
Socio-economic state:	Low ☐ moderate ☐ high ☐

Vaccination history: **Compulsory vaccinations:** **Other vaccinatians**	BCG (1st 3 months.) ☐ **Polio**: 2 months ☐ 4 months ☐ 6 months ☐ 18 months ☐ **DPT** : 2 months ☐ 4 months ☐ 6 months ☐ 18 months ☐ **Hepatitis B:** 2 months ☐ 4 months ☐ 6 months ☐ **Measles**: 9 months ☐ **MMR**: 18 months ☐ Hib ☐ Chickenpox ☐ Hepatitis A ☐ Meningococcal vaecine ☐ Pneumococcal vaccine ☐
Past history:	**a- Clinicaly diagnosed chickenpox**: (fever ☐ maculopapular ras ☐ vesicle ☐ eruption ☐ crusting ☐ itching ☐ • **Age at time of the disease**: • **Duration of the disease:** • **Treatment:** • **Complications**(pnennonia ☐ Encephalitis ☐ Guillian Baré syndron ☐ other complications **b- Other diseases with rash.** **c- Other diseases.** **d- Exposure to chickenpox:** Sibling ☐ Classmate ☐ Age on exposure

Present history :	Acute disease ☐ Chronic disease ☐ Medications. ☐
Family History :	Any sibling with clinically diagnosed chickenpox ☐ Other diseases.